Health Catalyst (HCAT) Scheduled to Post Earnings on Wednesday

Health Catalyst (NASDAQ:HCAT) will release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Health Catalyst to post earnings of $0.10 per share for the quarter. Health Catalyst has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.04. The firm had revenue of $75.90 million for the quarter, compared to the consensus estimate of $74.96 million. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The business’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.21) EPS. On average, analysts expect Health Catalyst to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Health Catalyst Stock Down 0.9 %

HCAT stock opened at $7.70 on Monday. Health Catalyst has a twelve month low of $5.42 and a twelve month high of $11.41. The business has a fifty day moving average of $7.95 and a 200-day moving average of $7.07. The company has a market cap of $465.62 million, a P/E ratio of -5.13 and a beta of 1.32.

Analyst Ratings Changes

Several equities analysts have recently issued reports on HCAT shares. Stephens decreased their target price on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. JPMorgan Chase & Co. boosted their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Piper Sandler decreased their price target on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. Finally, Evercore ISI upped their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Health Catalyst presently has an average rating of “Moderate Buy” and an average price target of $11.90.

Insider Transactions at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total value of $40,005.12. Following the sale, the chief operating officer now directly owns 134,899 shares in the company, valued at approximately $1,036,024.32. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the transaction, the chief operating officer now directly owns 134,899 shares of the company’s stock, valued at $1,036,024.32. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,187 shares of company stock valued at $226,171 over the last 90 days. 2.50% of the stock is owned by corporate insiders.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.